Products - Chronic kidney disease | Topic

Showing 15 products

Date | Title

Product type: GuidanceRemove ‘Product type: Guidance’ filter
New and updated: New in the last 6 monthsRemove ‘New and updated: New in the last 6 months’ filter

Vadadustat for treating symptomatic anaemia in adults having dialysis for chronic kidney disease (TA1035)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
23 January 2025
Sparsentan for treating primary IgA nephropathy [ID6308]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
25 June 2025
Dapagliflozin for treating chronic kidney disease [ID6411]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
2 July 2025
Targeted-release budesonide for treating primary IgA nephropathy (review of TA937) [ID6485]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
17 December 2025
Iptacopan for treating complement 3 glomerulopathy [ID6283]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
8 January 2026
Obinutuzumab with immunosuppressive therapies for treating lupus nephritis [ID6420]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
11 March 2026
Glucarpidase for reducing toxic plasma methotrexate levels in people aged 28 days and over [TSID10761]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Bardoxolone methyl for treating chronic kidney disease in people 12 years and over with Alport syndrome [TSID9998]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Nedosiran treating primary hyperoxaluria type 1 in people 6 years and over [TSID11777]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Sirolimus-eluting collagen implant for creating vascular access for haemodialysis in end-stage kidney disease [TSID9147]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Irbesartan–propagermanium for treating focal segmental glomerulosclerosis in people 12 years and over having an angiotensin II receptor blocker [ID6469]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pegcetacoplan for treating primary complement 3 glomerulopathy and primary immune-complex membranoproliferative glomerulonephritis in people 12 years and over [ID6489]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Sibeprenlimab for treating IgA nephropathy [TSID12111]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Veverimer for treating metabolic acidosis in chronic kidney disease [ID3832]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Atrasentan for treating primary IgA nephropathy [ID6588]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC

Chronic kidney disease Products

Filter

Product type
1 selected

Guidance programme

Status

New and updated
1 selected

Showing 15 products

Vadadustat for treating symptomatic anaemia in adults having dialysis for chronic kidney disease (TA1035)

Sparsentan for treating primary IgA nephropathy [ID6308]

Dapagliflozin for treating chronic kidney disease [ID6411]

Targeted-release budesonide for treating primary IgA nephropathy (review of TA937) [ID6485]

Iptacopan for treating complement 3 glomerulopathy [ID6283]

Obinutuzumab with immunosuppressive therapies for treating lupus nephritis [ID6420]

Glucarpidase for reducing toxic plasma methotrexate levels in people aged 28 days and over [TSID10761]

Bardoxolone methyl for treating chronic kidney disease in people 12 years and over with Alport syndrome [TSID9998]

Nedosiran treating primary hyperoxaluria type 1 in people 6 years and over [TSID11777]

Sirolimus-eluting collagen implant for creating vascular access for haemodialysis in end-stage kidney disease [TSID9147]

Irbesartan–propagermanium for treating focal segmental glomerulosclerosis in people 12 years and over having an angiotensin II receptor blocker [ID6469]

Pegcetacoplan for treating primary complement 3 glomerulopathy and primary immune-complex membranoproliferative glomerulonephritis in people 12 years and over [ID6489]

Sibeprenlimab for treating IgA nephropathy [TSID12111]

Veverimer for treating metabolic acidosis in chronic kidney disease [ID3832]

Atrasentan for treating primary IgA nephropathy [ID6588]

Chronic kidney disease Products

Filter

Product type1 selected

Guidance programme

Status

New and updated1 selected

Showing 15 products

Product type
1 selected

New and updated
1 selected